Drug Trial Radar · NCT06332170
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
610
Planned (sponsor's estimate)
Start
Apr 26, 2024
Primary completion
May 30, 2026
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Conditions
- Advanced Solid Tumor
Interventions
HS-20093Drug
administered as an IV infusion
AdebrelimabDrug
administered as an IV infusion
Cisplatin/ CarboplatinDrug
administered as an IV infusion
CetuximabDrug
administered as an IV infusion
EnzalutamideDrug
160mg once daily (QD) orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) for combination-treatmentsTime frame: Up to day 21 from the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.